cifenline has been researched along with Arrhythmia in 35 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multicentre, randomized, double-blind study, conducted in parallel groups, was designed to compare the efficacy and safety of cibenzoline (C) and oral propafenone (P) in the prevention of recurrent atrial arrhythmias (M) over a 6-month period." | 9.08 | [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. ( Bleinc, D; Canler, A; Lardoux, H; Maison Blanche, P; Marchand, X; Péraudeau, P; Rouesnel, P; Scheck, F, 1996) |
| "This study was designed to compare the efficacy and safety of cibenzoline and quinidine in ambulatory patients with ventricular arrhythmias." | 9.06 | Crossover comparison of cibenzoline and quinidine in ambulatory patients with chronic ventricular arrhythmias. ( Esterbrooks, DJ; Hansen, JM; Hilleman, DE; Mohiuddin, SM; Mooss, AN; Woodruff, MP, 1989) |
| "We compared the clinical efficacy and safety of oral cibenzoline and quinidine in 13 patients with complex ventricular arrhythmias using a randomized, open-label, crossover study." | 9.05 | Comparative efficacy and safety of oral cibenzoline and quinidine in ventricular arrhythmias: a randomized crossover study. ( Barr, MJ; Saksena, S; Wasty, N, 1985) |
| "These arrhythmias are divided in 31 atrial fibrillation, 11 tachy-systoles, 18 atrial flutters." | 6.38 | [Comparative study of cibenzoline and flecainide administered via an intravenous route in reducing auricular arrhythmia]. ( Bajolet, A; Chabert, JP; Chapoutot, L; Ehrhard, V; Laudinat, JM; Metivet, F; Metz, D; Pollet, E; Taupin, JM, 1990) |
| " For this purpose, we plotted a dose-response curve for adrenaline by calculating the arrhythmic ratio, which is the number of ventricular ectopic beats induced by adrenaline divided by the total heart rate, and observed the changes in the arrhythmic ratio-adrenaline dose relation before and after administration of class I drugs." | 5.31 | QT-prolonging class I drug, disopyramide, does not aggravate but suppresses adrenaline-induced arrhythmias. Comparison with cibenzoline and pilsicainide. ( Aye, NN; Hashimoto, K; Miyamoto, S; Teramatsu, T; Zhu, B, 2000) |
| "The digoxin plasma levels were (mean +/- sem) 0." | 5.28 | [Combination of oral administration of cibenzoline and digoxin in patients with supraventricular arrhythmia]. ( Arnaud, R; Bine-Scheck, F; Garnier, LF; Pruvost, P; Wanszelbaum, H, 1992) |
| " With long-term use of cibenzoline, significant PVD suppression was noted at the end of three months but not afterward." | 5.27 | Cibenzoline for high-frequency ventricular arrhythmias: a short-term comparison with quinidine and a long-term follow-up. ( Flowers, NC; Maldonado, C; Palakurthy, PR; Sohi, G, 1987) |
| "This multicentre, randomized, double-blind study, conducted in parallel groups, was designed to compare the efficacy and safety of cibenzoline (C) and oral propafenone (P) in the prevention of recurrent atrial arrhythmias (M) over a 6-month period." | 5.08 | [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. ( Bleinc, D; Canler, A; Lardoux, H; Maison Blanche, P; Marchand, X; Péraudeau, P; Rouesnel, P; Scheck, F, 1996) |
| "This study was designed to compare the efficacy and safety of cibenzoline and quinidine in ambulatory patients with ventricular arrhythmias." | 5.06 | Crossover comparison of cibenzoline and quinidine in ambulatory patients with chronic ventricular arrhythmias. ( Esterbrooks, DJ; Hansen, JM; Hilleman, DE; Mohiuddin, SM; Mooss, AN; Woodruff, MP, 1989) |
| "We compared the clinical efficacy and safety of oral cibenzoline and quinidine in 13 patients with complex ventricular arrhythmias using a randomized, open-label, crossover study." | 5.05 | Comparative efficacy and safety of oral cibenzoline and quinidine in ventricular arrhythmias: a randomized crossover study. ( Barr, MJ; Saksena, S; Wasty, N, 1985) |
| "The efficacy of disopyramide (DP), mexiletine (MX), aprindine (AP) and cibenzoline (CZ) on ventricular arrhythmias was compared (single drug therapy)." | 3.67 | Therapeutic effectiveness and plasma levels of single or combination use of class I antiarrhythmic agents for ventricular arrhythmias. ( Furuya, H; Goto, Y; Tanabe, T; Yoshikawa, H, 1988) |
| "In 21 patients (17%) recurrence was documented by ECG or Holter monitoring, cibenzoline thus being effective in 83%." | 2.68 | Cibenzoline in the prevention of recurrence of supraventricular arrhythmias. ( el Allaf, D; Kormoss, N; Schifflers, E, 1995) |
| "The presenting arrhythmia was atrial fibrillation in 15 patients, atrial flutter in 5, ectopic atrial tachycardia in 11, and paroxysmal atrioventricular (AV) junctional reentrant tachycardia in 6 patients." | 2.68 | Intravenous cibenzoline in the management of acute supraventricular tachyarrhythmias. ( Bru, P; Cointe, R; Lévy, S; Paganelli, F; Ricard, P, 1995) |
| " In comparative trials, cibenzoline has demonstrated efficacy similar to or better than that of a variety of other class I antiarrhythmic drugs and was at least as well tolerated, with a more convenient dosage schedule." | 2.38 | Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias. ( Brogden, RN; Faulds, D; Fitton, A; Harron, DW, 1992) |
| "These arrhythmias are divided in 31 atrial fibrillation, 11 tachy-systoles, 18 atrial flutters." | 2.38 | [Comparative study of cibenzoline and flecainide administered via an intravenous route in reducing auricular arrhythmia]. ( Bajolet, A; Chabert, JP; Chapoutot, L; Ehrhard, V; Laudinat, JM; Metivet, F; Metz, D; Pollet, E; Taupin, JM, 1990) |
| " Serious adverse reactions necessitate a change in antiarrhythmic therapy, as opposed to lowering drug dosage to an ineffective level." | 2.37 | Antiarrhythmic drug therapy. Recent advances and current status. ( Somberg, J, 1985) |
| " For this purpose, we plotted a dose-response curve for adrenaline by calculating the arrhythmic ratio, which is the number of ventricular ectopic beats induced by adrenaline divided by the total heart rate, and observed the changes in the arrhythmic ratio-adrenaline dose relation before and after administration of class I drugs." | 1.31 | QT-prolonging class I drug, disopyramide, does not aggravate but suppresses adrenaline-induced arrhythmias. Comparison with cibenzoline and pilsicainide. ( Aye, NN; Hashimoto, K; Miyamoto, S; Teramatsu, T; Zhu, B, 2000) |
| " All patients had further cifenline dosage increases without success." | 1.29 | Loss of efficacy during long-term cifenline therapy: development of antiarrhythmic resistance? ( Hee, TT; Hilleman, DE; Hunter, CB; Mohiuddin, SM; Sketch, MH, 1993) |
| "The digoxin plasma levels were (mean +/- sem) 0." | 1.28 | [Combination of oral administration of cibenzoline and digoxin in patients with supraventricular arrhythmia]. ( Arnaud, R; Bine-Scheck, F; Garnier, LF; Pruvost, P; Wanszelbaum, H, 1992) |
| "Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i." | 1.28 | Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias. ( Haruno, A; Hashimoto, K; Matsuzaki, T, 1990) |
| "Thus, reentrant arrhythmias might be prevented by isoproterenol and triggered by propranolol." | 1.28 | Effects of isoproterenol and propranolol on pharmacologically induced depression of intraventricular conduction. ( Aupetit, JF; Bertrix, L; Faucon, G; Lancon, JP; Lang, J; Timour, Q, 1989) |
| "The one patient with no ventricular arrhythmia induced during the control study still had no arrhythmia induced while receiving cibenzoline." | 1.27 | Clinical efficacy and electrophysiologic effects of cibenzoline therapy in patients with ventricular arrhythmias. ( Browne, KF; Chilson, DA; Heger, JJ; Prystowsky, EN; Zipes, DP, 1984) |
| "In five of the six patients with arrhythmia in whom VC data were also evaluated, the individual C90 for VCs were considerably less than those for PVCs." | 1.27 | Cibenzoline plasma concentration and antiarrhythmic effect. ( Aogaichi, K; Brazzell, RK; Carliner, NH; Heger, JJ; Morganroth, J; Somberg, JC, 1984) |
| "Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1." | 1.27 | Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias. ( Akiyama, K; Hashimoto, K; Mitsuhashi, H, 1987) |
| " With long-term use of cibenzoline, significant PVD suppression was noted at the end of three months but not afterward." | 1.27 | Cibenzoline for high-frequency ventricular arrhythmias: a short-term comparison with quinidine and a long-term follow-up. ( Flowers, NC; Maldonado, C; Palakurthy, PR; Sohi, G, 1987) |
| "Fifteen patients with ventricular premature complexes (VPCs) were included in this open study designed to assess the relative efficacy of bid (two times daily) and tid (three times daily) dosing regimens for cibenzoline as compared with qid (four times daily) administration." | 1.27 | Evaluation of dosing interval and optimum dose of cibenzoline. ( Aogaichi, K; Butler, B; Somberg, JC; Tepper, D; Zempol, P, 1987) |
| " Cibenzoline therapy resulted in adverse effects 18 patients and necessitated discontinuing therapy in 12." | 1.27 | Efficacy and safety of oral cibenzoline for ventricular arrhythmias. ( Horwitz, LD; Klein, RC; Rushforth, N, 1986) |
| " Plasma elimination half-life was prolonged, with values ranging from 7:4 to 23." | 1.27 | Pharmacokinetics of cibenzoline in patients with renal impairment. ( Aubert, P; Baglin, A; Canal, M; Flouvat, B; Guedon, J; Prinseau, J, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (42.86) | 18.7374 |
| 1990's | 15 (42.86) | 18.2507 |
| 2000's | 5 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kostis, JB | 1 |
| Krieger, S | 1 |
| Moreyra, A | 1 |
| Cosgrove, N | 1 |
| Heger, JJ | 3 |
| Prystowsky, EN | 2 |
| Zipes, DP | 2 |
| Browne, KF | 1 |
| Chilson, DA | 1 |
| Brazzell, RK | 1 |
| Aogaichi, K | 2 |
| Somberg, JC | 2 |
| Carliner, NH | 1 |
| Morganroth, J | 1 |
| el Allaf, D | 1 |
| Schifflers, E | 1 |
| Kormoss, N | 1 |
| Bru, P | 1 |
| Cointe, R | 1 |
| Paganelli, F | 1 |
| Ricard, P | 1 |
| Lévy, S | 1 |
| Mohiuddin, SM | 2 |
| Hee, TT | 1 |
| Hunter, CB | 1 |
| Hilleman, DE | 2 |
| Sketch, MH | 1 |
| Aupetit, JF | 3 |
| Timour, Q | 3 |
| Larbre, JP | 2 |
| Loufoua-Moundanga, J | 2 |
| Kioueh, I | 1 |
| Lopez, M | 1 |
| Faucon, G | 3 |
| Esato, M | 1 |
| Shimizu, A | 1 |
| Chun, YH | 1 |
| Tatsuno, H | 1 |
| Yamagata, T | 1 |
| Matsuzaki, M | 1 |
| Lardoux, H | 1 |
| Maison Blanche, P | 1 |
| Marchand, X | 1 |
| Canler, A | 1 |
| Rouesnel, P | 2 |
| Bleinc, D | 1 |
| Péraudeau, P | 1 |
| Scheck, F | 1 |
| Wakutani, Y | 1 |
| Matsushima, E | 1 |
| Son, A | 1 |
| Shimizu, Y | 1 |
| Goto, Y | 2 |
| Ishida, H | 1 |
| Honda, T | 2 |
| Soejima, H | 1 |
| Sasayama, T | 1 |
| Horimoto, M | 1 |
| Takeda, T | 1 |
| Takenaka, T | 1 |
| Inoue, H | 1 |
| Igarashi, K | 1 |
| Akino, M | 1 |
| Kikuchi, K | 1 |
| Miyamoto, S | 1 |
| Zhu, B | 1 |
| Teramatsu, T | 1 |
| Aye, NN | 1 |
| Hashimoto, K | 3 |
| Devos, D | 1 |
| Defebvre, L | 1 |
| Destée, A | 1 |
| Caron, J | 1 |
| Saikawa, T | 1 |
| Arita, M | 1 |
| Yamaguchi, K | 1 |
| Ito, M | 1 |
| Garnier, LF | 1 |
| Bine-Scheck, F | 2 |
| Pruvost, P | 1 |
| Wanszelbaum, H | 1 |
| Arnaud, R | 2 |
| Harron, DW | 1 |
| Brogden, RN | 1 |
| Faulds, D | 1 |
| Fitton, A | 1 |
| Vaughan Williams, EM | 1 |
| Babuty, D | 1 |
| Cosnay, P | 1 |
| Fauchier, JP | 1 |
| Haruno, A | 1 |
| Matsuzaki, T | 1 |
| Gutknecht, J | 1 |
| Larrey, D | 1 |
| Ychou, M | 1 |
| Fedkovic, Y | 1 |
| Janbon, C | 1 |
| Gerentes-Chassagne, I | 1 |
| Metz, D | 1 |
| Chapoutot, L | 1 |
| Laudinat, JM | 1 |
| Ehrhard, V | 1 |
| Taupin, JM | 1 |
| Chabert, JP | 1 |
| Metivet, F | 1 |
| Pollet, E | 1 |
| Bajolet, A | 1 |
| Akiyama, K | 1 |
| Mitsuhashi, H | 1 |
| Woodruff, MP | 1 |
| Esterbrooks, DJ | 1 |
| Mooss, AN | 1 |
| Hansen, JM | 1 |
| Lang, J | 1 |
| Lancon, JP | 1 |
| Bertrix, L | 1 |
| Somberg, J | 1 |
| Atarashi, H | 1 |
| Iida, K | 1 |
| Kou, M | 1 |
| Hirayama, Y | 1 |
| Gotoh, M | 1 |
| Ino, T | 1 |
| Katoh, T | 1 |
| Hayakawa, H | 1 |
| Tanabe, T | 1 |
| Yoshikawa, H | 1 |
| Furuya, H | 1 |
| Palakurthy, PR | 1 |
| Maldonado, C | 1 |
| Sohi, G | 1 |
| Flowers, NC | 1 |
| Zempol, P | 1 |
| Butler, B | 1 |
| Tepper, D | 1 |
| Klein, RC | 1 |
| Horwitz, LD | 1 |
| Rushforth, N | 1 |
| Canal, M | 1 |
| Flouvat, B | 1 |
| Aubert, P | 1 |
| Guedon, J | 1 |
| Prinseau, J | 1 |
| Baglin, A | 1 |
| Wasty, N | 1 |
| Saksena, S | 1 |
| Barr, MJ | 1 |
4 reviews available for cifenline and Arrhythmia
| Article | Year |
|---|---|
Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Imidazoles | 1992 |
Classifying antiarrhythmic actions: by facts or speculation.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Encainide; Flecaini | 1992 |
[Comparative study of cibenzoline and flecainide administered via an intravenous route in reducing auricular arrhythmia].
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Flecainide; Hu | 1990 |
Antiarrhythmic drug therapy. Recent advances and current status.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrh | 1985 |
10 trials available for cifenline and Arrhythmia
| Article | Year |
|---|---|
Cibenzoline for treatment of ventricular arrhythmias: a double-blind placebo-controlled study.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Me | 1984 |
Cibenzoline in the prevention of recurrence of supraventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease-Free Survival; Electrocardiograph | 1995 |
Intravenous cibenzoline in the management of acute supraventricular tachyarrhythmias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fib | 1995 |
Electrophysiologic effects of a class I antiarrhythmic agent, cibenzoline, on the refractoriness and conduction of the human atrium in vivo.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Electrophysiology; Heart Atria; H | 1996 |
[Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation | 1996 |
Long-term low-dose cibenzoline in patients with chronic renal failure undergoing hemodialysis.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Dose-Respon | 2000 |
Hypoglycemic effect of cibenzoline in patients with abnormal glucose tolerance and frequent ventricular arrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Glucose; Female; Glucose Tolerance Test; G | 2000 |
[Comparison of the efficacy/tolerability ratio of cibenzoline and propafenone in the treatment of ventricular arrhythmia].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Female; Humans; Imidazoles; Male; | 1992 |
Crossover comparison of cibenzoline and quinidine in ambulatory patients with chronic ventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Clinical Trials as Topic | 1989 |
Comparative efficacy and safety of oral cibenzoline and quinidine in ventricular arrhythmias: a randomized crossover study.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Imidazoles; Male; Middle | 1985 |
21 other studies available for cifenline and Arrhythmia
| Article | Year |
|---|---|
Drug therapy of cardiac arrhythmias.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Biological Availabili | 1983 |
Clinical efficacy and electrophysiologic effects of cibenzoline therapy in patients with ventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Electrocardio | 1984 |
Cibenzoline plasma concentration and antiarrhythmic effect.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Drug Eval | 1984 |
Loss of efficacy during long-term cifenline therapy: development of antiarrhythmic resistance?
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Resistance; Electrocardiography, Amb | 1993 |
Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia--study in the porcine in situ heart.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 1993 |
Myasthenialike syndrome due to adverse effects of cibenzoline in a patient with chronic renal failure.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electric Stimulation; Heart Ventricle | 1998 |
[Efficacy of cibenzoline for chest oppression and ventricular arrhythmia during effort and alcohol consumption in a patient with hypertrophic obstructive cardiomyopathy: a case report].
Topics: Administration, Oral; Aged; Alcohol Drinking; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomy | 2000 |
QT-prolonging class I drug, disopyramide, does not aggravate but suppresses adrenaline-induced arrhythmias. Comparison with cibenzoline and pilsicainide.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Disopyramide; Dogs; Drug Inte | 2000 |
Choreic movements induced by cibenzoline: an Ic class antiarrhythmic effect?
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chorea; Dopamine Antagonists; Dyskinesia, Drug-I | 2000 |
[Combination of oral administration of cibenzoline and digoxin in patients with supraventricular arrhythmia].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 1992 |
Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channels; Dogs; Epinephrine; Heart Ve | 1990 |
[Severe ischemic hepatitis after taking cibenzoline].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biopsy; Cardiac Output; Hepatitis; Humans; Imida | 1991 |
[Arrhythmogenic risk of antiarrhythmic drugs: study with class Ic drugs during myocardial ischemia].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Coronary Disease; | 1991 |
Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Digitalis Glycosides; Dogs; Epinephrine; Fema | 1987 |
Effects of isoproterenol and propranolol on pharmacologically induced depression of intraventricular conduction.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Depression, Chemical; Dogs; E | 1989 |
[Electrophysiologic effects of intravenous cibenzoline succinate, a new class I antiarrhythmic agent].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Electrophysi | 1988 |
Therapeutic effectiveness and plasma levels of single or combination use of class I antiarrhythmic agents for ventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Chronic Disease; Disopyramide; | 1988 |
Cibenzoline for high-frequency ventricular arrhythmias: a short-term comparison with quinidine and a long-term follow-up.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Follow-Up Stud | 1987 |
Evaluation of dosing interval and optimum dose of cibenzoline.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Drug Ad | 1987 |
Efficacy and safety of oral cibenzoline for ventricular arrhythmias.
Topics: Administration, Oral; Adolescent; Adult; Aged; Arrhythmias, Cardiac; Electrocardiography; Female; He | 1986 |
Pharmacokinetics of cibenzoline in patients with renal impairment.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Creatinine; Female; Half-Life; Humans; Im | 1985 |